EP Patent

EP3002274A1 — Treprostinil monohydrate

Assigned to United Therapeutics Corp · Expires 2016-04-06 · 10y expired

What this patent protects

There is provided a stable monohydrate form of treprostinil and pharmaceutical formulation comprising the same, method of making and using the same.

USPTO Abstract

There is provided a stable monohydrate form of treprostinil and pharmaceutical formulation comprising the same, method of making and using the same.

Drugs covered by this patent

treprostinil-diolamine (TREPROSTINIL DIOLAMINE)

Patent Metadata

Patent number: EP3002274A1
Jurisdiction: EP
Classification: —
Expires: 2016-04-06
Drug substance claim: No
Drug product claim: No
Assignee: United Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.